BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?

Key Takeaways BDTX advances silevertinib for EGFRm NSCLC and GBM, with phase II data due in late 2025.ORIC progresses ORIC-944 and enozertinib, with multiple phase Ib and III studies planned through 2026.Despite BDTX's gains, ORIC's broader pipeline and stronger estimates make it the preferred biotech pick.Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage oncology company developing therapies that target families of oncogenic mutations in patients with cancer.ORIC Pharmaceuticals (ORIC) is also a ...